核心财务表现 - **季度营收**：2026年第一季度营收为2.6312亿美元，同比下降2.5%，但超出Zacks一致预期（2.5759亿美元）2.15% [1] - **每股收益**：季度每股收益为0.25美元，与Zacks一致预期持平，但较去年同期的0.13美元显著增长 [1] 关键运营指标 - **承保费用率**：为32.5%，低于两位分析师平均预估的33.8% [4] - **综合成本率**：为110.4%，高于两位分析师平均预估的109.4% [4] - **净损失率**：为77.9%，高于两位分析师平均预估的75.6% [4] - **净已赚保费**：为2.2351亿美元，高于四位分析师平均预估的2.1812亿美元 [4] 投资及其他收益 - **净投资收益**：为3997万美元，略高于四位分析师平均预估的3967万美元 [4] - **其他收入（损失）**：录得36万美元损失，而四位分析师平均预估为66万美元收益 [4] - **未合并子公司股权收益**：为294万美元，低于四位分析师平均预估的348万美元 [4] 市场表现与展望 - **股价表现**：过去一个月股价上涨1.9%，同期Zacks S&P 500综合指数上涨9.5% [3] - **市场评级**：目前Zacks Rank评级为1（强力买入），预示其近期可能跑赢大盘 [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Commission File Number: 0-16533 Table of Contents ProAssurance Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of Delaware 63-1261433 incorporation or organization) (I.R.S. Employer Identification No.) 100 Brookwood Place, Birmingham, AL 35209 (Address of principal executive offices) (Zip Code) (205) 877-4400 (Registrant's telephone number, including area code) | Title ...

Highlights (2) "ProAssurance has started 2026 with another quarter of progress toward our long-term objectives," said Ned Rand, President and Chief Executive Officer of ProAssurance. "Joining forces with The Doctors Company through the transaction we announced in March 2025 will allow our organizations to continue to serve today's healthcare providers with the necessary scale and breadth of capabilities. "Closing the transaction remains subject to approval from insurance regulators in the jurisdictions wher ...